Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 15/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29980480 | 1.00 | GLP1R (0.49) | GLP1RALDH1A1GLAMAPTHPGD | |
| SCHEMBL516638 | 0.84 | ALDH1A1 (0.45) | ALDH1A1GLAMAPTHPGDACHE | |
| SCHEMBL27581712 | 0.82 | ALDH1A1 (0.43) | GLP1RALDH1A1GLAMAPTHPGD | |
| SCHEMBL30908356 | 0.79 | ALDH1A1 (0.45) | GLP1RALDH1A1GLAMAPTHPGD | |
| SCHEMBL16077775 | 0.76 | TDP1 (0.54) | GLP1RALDH1A1HPGDKMT2AKDM4E | |
| SCHEMBL4960456 | 0.75 | ALDH1A1 (0.54) | ALDH1A1GLAMAPTHPGDACHE | |
| SCHEMBL30908510 | 0.71 | KDM4E (0.44) | GLP1RALDH1A1GLAMAPTHPGD | |
| Acridine SCHEMBL8000372 | 0.71 | ALDH1A1 (0.65) | ALDH1A1GLAMAPTHPGDACHE | |
| SCHEMBL1467074 | 0.71 | ALDH1A1 (0.59) | ALDH1A1GLAMAPTHPGDACHE | |
| Acridine SCHEMBL1051621 | 0.70 | ALDH1A1 (0.71) | ALDH1A1GLAMAPTHPGDACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11464770-B2 | Anticancer pharmaceutical composition | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-10-11 | — | — | US | disclosed |
| US-20210315879-A1 | ANTICANCER PHARMACEUTICAL COMPOSITION | NATIONAL CANCER CENTER (KR) | 2021-10-14 | — | — | US | disclosed |
| US-10227306-B2 | Compounds for inhibiting c-myc/max/DNA complex formation | NATIONAL CANCER CENTER (KR) | 2019-03-12 | — | — | US | disclosed |
| US-20180186744-A1 | COMPOUNDS FOR INHIBITING C-MYC/MAX/DNA COMPLEX FORMATION | NATIONAL CANCER CENTER (KR) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11464770-B2 | Anticancer pharmaceutical composition | MYC, MYCBP, TP53 | GLP1R 4348/4885ALDH1A1 4368/4885GLA 2580/4885 |
| US-10227306-B2 | Compounds for inhibiting c-myc/max/DNA complex formation | MYC, MYCBP, MYCBP2 | GLP1R 4402/4885ALDH1A1 4129/4885GLA 3314/4885 |
| US-20180186744-A1 | COMPOUNDS FOR INHIBITING C-MYC/MAX/DNA COMPLEX FORMATION | MYC, MYCBP, MYCBP2 | GLP1R 4402/4885ALDH1A1 4129/4885GLA 3314/4885 |
| US-20210315879-A1 | ANTICANCER PHARMACEUTICAL COMPOSITION | MYC, MYCBP, TP53 | GLP1R 4348/4885ALDH1A1 4368/4885GLA 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.